NCT03383575View on ClinicalTrials.gov

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 17, 2018

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic LeukemiaIDH2 Gene MutationMyelodysplastic Syndrome With Excess BlastsRecurrent High Risk Myelodysplastic SyndromeRefractory High Risk Myelodysplastic Syndrome
Interventions
DRUG

Azacitidine

Given IV or SC

DRUG

Enasidenib

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (3)

21287

ACTIVE_NOT_RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

44195

ACTIVE_NOT_RECRUITING

Cleveland Clinic Foundation, Cleveland

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celgene

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER